Aims: To analyze the association between any past month cannabis use and advanced liver fibrosis.
Background: Cannabinoid receptors play a role in acute and chronic liver injury, but human studies addressing the impact of cannabis use on liver fibrosis have shown mixed results.
Objectives: To explore and estimate the association between past month cannabis use and advanced liver fibrosis (ALF) in a cohort of Russian HIV-positive individuals with heavy alcohol use and high prevalence of hepatitis C virus (HCV) coinfection.
Methods: Baseline data were analyzed from participants of the ZINC study, a trial that enrolled HIV-positive Russian patients without prior antiretroviral therapy. Cannabis use during the prior month was assessed at study entry. ALF was defined as FIB-4>3.25 and/or APRI>1.5, transient elastography was used to detect advanced liver fibrosis among participants with FIB-4 values in the intermediate range (between 1.45 and 3.25).
Results: Participants (n=248) were mostly male (72.6%), young (median age of 33.9 years), infected with HCV (87.9%) and not with advanced immunosuppression (median CD4 count 462). Cannabis use was uncommon (12.4%) and the prevalence of advanced liver disease was 21.7%. The prevalence of ALF was similar among those who used cannabis compared to those who did not (25.8% vs. 21.7%). We were unable to detect an association between cannabis use and ALF (adjusted odds ratio: 1.28, 95% confidence interval: 0.53-3.12, p=0.59) in logistic regression models adjusting for age, sex, heavy drinking, BMI and CD4 cell count.
Conclusion: In this exploratory study among HIV-positive heavy drinking Russians we did not detect an association between recent cannabis use and ALF. Larger scale studies including more participants with cannabis use are needed to further examine this relationship.
Keywords: Alcohol; Cannabis; FIB-4.; HCV; HIV; Liver fibrosis.
Copyright© Bentham Science Publishers; For any queries, please email at firstname.lastname@example.org.